Physician profile
Jonathan Thomas Kiser
NPI 1235866484
$3,680.51
in general payments reported to CMS, 2019-2025
18 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $567 · 2024: $1,729 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,534 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,533.91 |
| Education | $146.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $794.25 | 2024-2025 | Tremfya |
| Abbvie INC. | $577.92 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $400.79 | 2024-2025 | |
| Leo Pharma INC. | $300.21 | 2023-2025 | Adbry, Anzupgo |
| Amgen INC. | $270.82 | 2024-2025 | Otezla, Otezla |
| Genzyme Corporation | $264.31 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $191.75 | 2023 | Sotyktu |
| Dermavant Sciences, INC. | $155.06 | 2024 | Vtama |
| Pfizer INC. | $149.50 | 2024-2025 | |
| Lilly USA, LLC | $125.40 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $90.45 | 2023-2025 | Dupixent |
| Ucb, INC. | $82.98 | 2023-2024 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $81.68 | 2023-2025 | Odomzo, Blu-U |
| Arcutis Biotherapeutics, INC. | $59.07 | 2024-2025 | Zoryve |
| Galderma Laboratories, L.P. | $57.04 | 2024-2025 | Nemluvio |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $45.09 | 2025 | Hadlima |
| Kyowa Kirin, INC. | $19.47 | 2024 | Poteligeo |
| Pharming Healthcare, INC. | $14.72 | 2024 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Kiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.